E Cannabis Central: Pure-Play Pot Stock Portfolio Performed Poorly Again Last Week

The majority of the 25 stocks in the munKNEE.com Pure-Play Pot Stock Portfolio performed poorly for the trading week ending September 11th, going down 3.1% on the heels of a 6.9% decline the previous week. 21 of the constituents declined and all 4 of the industry categories declined as well. The winners and losers are as follows:

Major Winners

Only four of the stocks in the portfolio finished the week up in price but none went up by 10% or more and only 2 were up more than 5%, namely, Jushi which was up 8.4% and Medicine Man which was up 7.7%. Green Thumb advanced by a meager 0.4%.

Major Losers

21 of the stocks in the portfolio finished the week down in price with four going down by at least 9.7%, namely:

  1. Aurora (ACB) -18.0% on the heels of -13.3% the previous week
  2. cbdMD (YCBD) -16.4% on the heels of -12.2% the previous week
  3. Tilray (TLRY) -10.3% on the heels of -10.2% the previous week
  4. Greenlane (GNLN) -9.7%

The 25 munKNEE.com Pure-Play Pot Stock Portfolio includes companies doing business in 4 categories based on their primary area of focus in the cannabis industry. The categories are identified below with how they performed given the performance of the stocks in the portfolio that make up each category:

  1. The Vertically Integrated (i.e. Seed-to-Sale) Category has 21 portfolio participants that grow, process, and sell cannabis and hemp flower and related products and they went down 2.9%, on average.
  2. The Extraction Category has 2 portfolio participants (NEPT and VLNCF) focused on the extraction of cannabis compounds and their infusion into consumer products and they went down 4.8%, on average.
  3. The Consumption Devices Category has only 1 portfolio participant  (GNLN) focused on developing and selling personal consumption devices for cannabis consumers such as vape pens and inhalers and it went down 9.7% in price.
  4. The Biotechnology Category has only 1 portfolio participant (AVCNF) which markets new drugs utilizing cannabinoids (CBD) and it went down 6.1% in price.
1 2
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.